Steven Katzman, DO
Internal Medicine · Livonia, MINPI 1700992054
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $550,102 of the $715,397 with a category attached, or 76.9%. 46 manufacturers reported payments, led by Amgen at 52.9% of the total. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,380 payments — averaging $518.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$379K
- Novo Nordisk$138K
- Johnson & Johnson$108K
- Boehringer Ingelheim$26K
- Ironwood Pharmaceuticals, Inc$15K
- AbbVie$11K
- plus $39K from 40 others
Across 250 payments — averaging $9339.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.8M
- Merck$411K
- Janssen Research & Development, LLC$40K
- Genentech, Inc.$23K
- Karyopharm Therapeutics Inc.$15K
- Vanda Pharmaceuticals Inc.$15K
- plus $13K from 2 others
What the payments were for
- Consulting fees$46,7517%
- Speaking & faculty fees$550,10277%
- Travel & lodging$92,70113%
- Food & beverage$25,7934%
- Education$290%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$305,548
- XARELTO$82,088
- Repatha$66,631
- RYBELSUS$63,740
- Ozempic$31,161
- Victoza$30,904
- LINZESS$24,119
- INVOKANA$22,999
- JARDIANCE$20,053
- PAXLOVID$9,567
- LONHALA MAGNAIR$7,152
- CeQur Simplicity$6,723
- NUCALA$3,040
- TRELEGY ELLIPTA$2,190
- BEVESPI AEROSPHERE$750
- CHARTIS CATHETER$135
- ZEPHYR ENDOBRONCHIAL VALVE$135
- PULMONX CHARTIS TABLET CONSOLE$135
- ZEPHYR DELIVERY CATHETER$135
- EVENITY$125
How this compares
$715,397 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 135 | $151,871 |
| OzempicSemaglutide | 47 | $59,461 |
| EliquisApixaban | 45 | $56,794 |
| LinzessLinaclotide | 38 | $46,463 |
| Repatha SureclickEvolocumab | 36 | $42,386 |
| JardianceEmpagliflozin | 38 | $39,528 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $37,557 |
| JanuviaSitagliptin Phosphate | 18 | $22,663 |
| TrulicityDulaglutide | 16 | $22,560 |
| InvokanaCanagliflozin | 14 | $20,166 |
| FarxigaDapagliflozin Propanediol | 18 | $19,726 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $19,128 |
| Spiriva RespimatTiotropium Bromide | 17 | $14,520 |
| TradjentaLinagliptin | 14 | $13,962 |
| MyrbetriqMirabegron | 16 | $13,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Invokana | $107,970 | $172,037149 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat | $26,003 | $76,76881 claims |
| Novo NordiskOzempic | $138,050 | $59,46147 claims |
| PfizerEliquis | $9,899 | $56,79445 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $6,523 | $56,68662 claims |
| AbbVieLinzess, Synthroid | $10,669 | $48,31860 claims |
| MerckJanuvia | $24 | $22,66318 claims |
| Lilly USA, LLCTrulicity | $5,057 | $22,56016 claims |
| AstraZenecaFarxiga | $978 | $19,72618 claims |
| Astellas Pharma US IncMyrbetriq | $186 | $13,57016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Livonia
- Ala ShukerLivonia$21K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.